A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

Holland, TL, O'Riordan, W, McManus, A et al. (12 more authors) (2018) A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrobial Agents and Chemotherapy, 62 (5). e02580-17. ISSN 0066-4804

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 American Society for Microbiology. This is an author produced version of a paper published in Antimicrobial Agents and Chemotherapy. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: iclaprim; vancomycin; acute bacterial skin and skin structure infections; skin
Dates:
  • Published: May 2018
  • Accepted: 6 March 2018
  • Published (online): 12 March 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 23 Aug 2018 11:02
Last Modified: 23 Aug 2018 11:02
Status: Published
Publisher: American Society for Microbiology
Identification Number: https://doi.org/10.1128/AAC.02580-17
Related URLs:

Share / Export

Statistics